I agree, quarterly updates are just updates, not PR's. I mostly hope we get details of what and why the FDA is asking for in the clinical hold lift. Why do they need a protocol? is all the extra asks beyond the safety of Leronlimab leading to an approval path despite Cytodyn abandoning the BLA? etc..